Bristol's Opdivo/Yervoy Combo Beats Sutent On Survival In Renal Cancer
The combination of Opdivo and Yervoy showed a survival advantage in renal cancer in a Phase III trial, adding to the understanding that overall survival may be a better endpoint than progression-free survival for measuring immuno-oncology drugs.
You may also be interested in...
Phase I/II data from Opdivo/Yervoy combination in SCLC provide more evidence that tumor mutation burden is emerging as a biomarker for immunotherapy, but commercial value is unclear and results don't have implications for the all-important CheckMate 227 non-small cell lung cancer trial, analysts say.
US FDA's Oncologic Drugs Advisory Committee will consider whether positive S-TRAC or negative ASSURE data should guide decision on expanding Sutent's renal cell carcinoma indication.
Bristol-Myers Squibb's Opdivo plus Yervoy in first-line RCC did not achieve statistical significance in terms of progression-free survival versus Sutent, but overall survival data aren't available yet.